Related references
Note: Only part of the references are listed.Three Years Follow-up of Pamidronate Therapy in Two Brothers with Osteoporosis-Pseudoglioma Syndrome (OPPG) Carrying an LRP5 Mutation
E.R. Barros et al.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM (2011)
Genetic Analysis of Lrp5 Function in Osteoblast Progenitors
Vijay K. Yadav et al.
CALCIFIED TISSUE INTERNATIONAL (2010)
Therapy of hypoparathyroidism with intact parathyroid hormone
M. R. Rubin et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Retreatment With Teriparatide One Year After the First Teriparatide Course in Patients on Continued Long-Term Alendronate
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Osteoporosis-pseudoglioma syndrome: Description of 9 new cases and beneficial response to bisphosphonates
Elizabeth A. Streeten et al.
BONE (2008)
Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum
Vijay K. Yadav et al.
CELL (2008)
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate
Paul D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A novel mutation in the LRP5 gene is associated with osteoporosis-pseudoglioma syndrome
E. R. Barros et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium
Robert Lindsay et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment
Kimihiko Sawakami et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Clinical and molecular findings in osteoporosis-pseudoglioma syndrome
MR Ai et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2005)
SOST is a target gene for PTH in bone
H Keller et al.
BONE (2005)
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
B Ettinger et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Long-term treatment of hypoparathyroidism:: A randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium
KK Winer et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development
YQ Gong et al.
CELL (2001)
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
MR Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Primary prevention of gluccocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone
Y Boutsen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers
ES Kurland et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Share Paper
